Panitumumab Associated Acute Pancreatitis

Area of Science:

• Oncology
• Gastroenterology
• Pharmacology

Background:

• Panitumumab combined with chemotherapy improves survival in wild-type metastatic colon cancer.
• While skin toxicities are common, other adverse events require further investigation.
• This case explores a potential link between panitumumab and acute pancreatitis.

Observation:

• A 67-year-old patient with sigmoid colon cancer and liver metastases developed acute pancreatitis shortly after initiating panitumumab therapy.
• The patient presented with abdominal pain, leading to hospitalization and diagnosis of acute pancreatitis via abdominal tomography.
• Treatment involved fluid resuscitation and cessation of oral intake, resulting in symptom resolution.

Findings:

• Acute pancreatitis is a rare but potential adverse effect of panitumumab treatment.
• This case represents the first reported instance of panitumumab-induced acute pancreatitis in the context of metastatic colon cancer therapy.
• The temporal association suggests panitumumab as a possible etiological factor.

Implications:

• Clinicians should consider acute pancreatitis in patients receiving panitumumab who present with abdominal pain.
• Further research is needed to elucidate the mechanism and incidence of panitumumab-related pancreatitis.
• This finding may influence treatment protocols and patient monitoring for metastatic colon cancer.